Characteristics and function of the gut microbiota in patients with IgA nephropathy via metagenomic sequencing technology.
Humans
Glomerulonephritis, IGA
/ microbiology
Gastrointestinal Microbiome
/ genetics
Male
Female
Adult
Feces
/ microbiology
Metagenomics
/ methods
Case-Control Studies
Middle Aged
Moraxella
/ isolation & purification
Escherichia coli
/ isolation & purification
Acinetobacter
/ isolation & purification
Metagenome
Young Adult
IgA nephropathy
gut microbiota
metagenomic sequencing
microbial characteristics and functions
Journal
Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128
Informations de publication
Date de publication:
Dec 2024
Dec 2024
Historique:
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
23
8
2024
Statut:
ppublish
Résumé
The aim of this study was to investigate the characteristics and related functional pathways of the gut microbiota in patients with IgA nephropathy (IgAN) through metagenomic sequencing technology. We enrolled individuals with primary IgAN, including patients with normal and abnormal renal function. Additionally, we recruited healthy volunteers as the healthy control group. Stool samples were collected, and species and functional annotation were performed through fecal metagenome sequencing. We employed linear discriminant analysis effect size (LEfSe) analysis to identify significantly different bacterial microbiota and functional pathways. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was used to annotate microbiota functions, and redundancy analysis (RDA) was performed to analyze the factors affecting the composition and distribution of the gut microbiota. LEfSe analysis revealed differences in the gut microbiota between IgAN patients and healthy controls. The characteristic microorganisms in the IgAN group were classified as The status of the gut microbiota is closely associated not only with the onset of IgAN but also with the renal function of IgAN patients. The characteristic gut microbiota may serve as a promising diagnostic biomarker and therapeutic target for IgAN.
Identifiants
pubmed: 39177227
doi: 10.1080/0886022X.2024.2393754
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM